PharmaDepth

Company profile

GILEAD SCIENCES, INC.

NASDAQ:GILDBiotechnology: Biological Products (No Diagnostic Substances)

Drug pipeline (61)

AssetStageRevenueTrialsStatus
BIKTARVYapproved$3.8B*Q2 202620approved
DESCOVYapproved$967.0M*Q2 202620approved
TRODELVYapproved$457.0MQ2 20260—
GENVOYAapproved$289.0M*Q2 202640approved
VEMLIDYapproved$289.0MQ2 20260—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (680)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT00768300phase3terminated2008-12-012011-02-01Gilead Sciences(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF
NCT00364026phase2completed2004-06-01—Gilead SciencesA Clinical Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Blood Pressure Lowering Drugs
NCT00002453—completed1999-12-01—Gilead SciencesA Compassionate Use Study of Tenofovir Disoproxil Fumarate as Treatment for HIV Infection
NCT00036634phase1_2completed2002-03-012003-02-01Gilead SciencesA Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients
NCT00578786phase3completed2004-02-012010-03-01Gilead SciencesA Long Term Study of Ambrisentan in Pulmonary Arterial Hypertension Subjects Having Completed AMB-320 (NCT00423748) or AMB-321 (NCT00423202)

FDA applications (38)

ApplicationApprovedTypeApplicantProducts
NDA 2211042026-08-27NDAGILEAD SCIENCES INC
NDA 2214432026-08-27NDAGILEAD SCIENCES INC
BLA 7614682026-05-22BLAGILEAD SCIENCES, INC.
NDA 2200182025-06-18NDAGILEAD SCIENCES INC
NDA 2200202025-06-18NDAGILEAD SCIENCES INC